Summary & Overview
HCPCS Level II J0153: Adenosine Injection, 1 mg
HCPCS Level II code J0153 denotes a 1 mg injection of adenosine (excluding adenosine phosphate compounds). Adenosine is an acute-acting intravenous medication used primarily in cardiac care, making this code relevant across hospital inpatient, outpatient, and emergency settings nationwide. The code matters for billing clarity when documenting short-acting antiarrhythmic therapy and for payers that process hospital and professional drug administration claims.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for adenosine use, typical sites of service, and the common modifiers listed for billing practice. The publication outlines expected benchmarking categories, billing considerations for injectable cardiac agents, and where data is not available in the input. This summary is intended to help coding, billing, and revenue teams understand the purpose of J0153, its clinical application, and the payer landscape relevant to national billing and reimbursement workflows.
Billing Code Overview
HCPCS Level II code J0153 describes an injection of adenosine, 1 mg. The descriptor clarifies that this code is not to be used to report any adenosine phosphate compounds. The service type is medication administration (intravenous injectable drug) provided when adenosine is ordered for clinical use.
Typical site of service for J0153 is hospital inpatient or outpatient settings and emergency departments, where rapid intravenous administration of adenosine is commonly performed for diagnostic or therapeutic cardiac indications such as supraventricular tachycardia management.
Clinical & Coding Specifications
Clinical Context
A patient in the emergency department presents with sudden onset palpitations, lightheadedness, and an irregular, rapid heart rhythm diagnosed as supraventricular tachycardia (SVT) on ECG. After initial assessment (vital signs, IV access, and monitoring), vagal maneuvers are attempted and unsuccessful. Adenosine is prepared for rapid IV push to terminate re-entrant SVT. A clinician (emergency medicine physician or cardiologist) confirms indication, ensures resuscitation equipment is available, explains the procedure to the patient or proxy, and administers J0153 (adenosine 1 mg per billing unit) as per institutional dosing protocol (commonly 6 mg rapid bolus followed by 12 mg if needed, using multiple units as required). Continuous ECG monitoring and blood pressure observation occur during and after administration; repeated doses are administered only if clinically indicated. Typical sites of service include hospital emergency departments, inpatient wards, observation units, and catheterization or procedural suites where acute supraventricular arrhythmias are treated. Patient scenario modifiers may include urgent/emergent status and documentation of medical necessity for IV pharmacologic cardioversion.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
59 | Distinct procedural service | When adenosine injection is billed with another procedure on the same day that is separate and distinct (different site or session) and documentation supports separateness |